Is Silence Therapeutics plc (SLN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 50.1% / 30% | 9.1% / 30% | 10.34% / 5% | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 50.1% / 33% | 9.1% / 33% | 10.34% / 5% | ✗ NOT HALAL |
| MSCI | 0.1% / 33% | 72.7% / 33% | 13.3% / 33% | 10.34% / 5% | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 50.1% / 33% | 9.1% / 33% | 10.34% / 5% | ✗ NOT HALAL |
| FTSE | 0.1% / 33% | 72.7% / 33% | 13.3% / 50% | 10.34% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 61.5% | |
| Operating Margin | -37150.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -90.3% | |
| Return on Assets (ROA) | -30.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$62M |
| Free Cash Flow | -$62M |
| Total Debt | $160,000 |
| Debt-to-Equity | 0.3 |
| Current Ratio | 8.7 |
| Total Assets | $131M |
Price & Trading
| Last Close | $5.31 |
| 50-Day MA | $5.46 |
| 200-Day MA | $5.82 |
| Avg Volume | 281K |
| Beta | 1.4 |
|
52-Week Range
$1.97
| |
About Silence Therapeutics plc (SLN)
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Silence Therapeutics plc (SLN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Silence Therapeutics plc is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Silence Therapeutics plc's debt ratio?
Silence Therapeutics plc's debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.1%.
What are Silence Therapeutics plc's key financial metrics?
Silence Therapeutics plc has a market capitalization of $233M, and revenue of $559,000. Return on equity stands at -90.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.